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Abstract
Background: Previous studies have demonstrated that the trafficking defects of Nav1.1/Nav1.2 are involved in the
dementia pathophysiology. However, the detailed mechanisms are not fully understood. Moreover, whether the
impaired miRNAs regulation linked to dementia is a key player in sodium channel trafficking disturbance remains
unclear. The cognitive impairment induced by chronic cerebral ischemia through chronic brain hypoperfusion
(CBH) is likely reason to precede dementia. Therefore, our goal in the present study was to examine the role of
microRNA-9 (miR-9) in regulating Nav1.1/Nav1.2 trafficking under CBH generated by bilateral common carotid
artery occlusion (2VO).
Results: The impairment of Nav1.1/Nav1.2 trafficking and decreased expression of Navβ2 were found in the
hippocampi and cortices of rats following CBH generated by bilateral 2VO. MiR-9 was increased in both the
hippocampi and cortices of rats following CBH by qRT-PCR. Intriguingly, miR-9 suppressed, while AMO-miR-9
enhanced, the trafficking of Nav1.1/Nav1.2 from cytoplasm to cell membrane. Further study showed that
overexpression of miR-9 inhibited the Navβ2 expression by targeting on its coding sequence (CDS) domain by
dual luciferase assay. However, binding-site mutation or miR-masks failed to influence Navβ2 expression as well
as Nav1.1/Nav1.2 trafficking process, indicating that Navβ2 is a potential target for miR-9. Lentivirus-mediated
miR-9 overexpression also inhibited Navβ2 expression and elicited translocation deficits to cell membrane of
Nav1.1/Nav1.2 in rats, whereas injection of lentivirus-mediated miR-9 knockdown could reverse the impaired
trafficking of Nav1.1/Nav1.2 triggered by 2VO.
Conclusions: We conclude that miR-9 may play a key role in regulating the process of Nav1.1/Nav1.2 trafficking
via targeting on Navβ2 protein in 2VO rats at post-transcriptional level, and inhibition of miR-9 may be a potentially
valuable approach to prevent Nav1.1/Nav1.2 trafficking disturbance induced by CBH.
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Background
Since voltage-gated sodium channel (VGSC) is necessary
in the initiation and propagation of action potentials in
neurons, it is a valuable therapeutic target for neurological
disorders, such as epilepsy and chronic neuropathic pain
[1–3]. Recent studies have now expanded the role of so-
dium channels in multi-neurological diseases including
autism, migraine and multiple sclerosis [2, 4, 5]. A pro-
spective study reported that Alzheimer's disease (AD)
have an increased risk of developing seizures and epi-
lepsy [6]. A recent study reported that over activity of
hippocampus might contribute to AD-related cognitive
decline [7] and antiepileptic drug was demonstrated to
reverse cognitive deficits and diminished the anxiety
phenotypes in AD mice [8]. And electrical imbalance
may contribute to cognitive deficits in AD and serve as
a target for clinical intervention [9, 10]. These studies
together suggest that dysfunction of VGSC may share
the common phenotype between AD and epilepsy.
Voltage-gated Na+ channels (VGSCs) are macromolecu-
lar protein complexes, which are composed of α-subunits
(Nav1.1–Nav1.9) and β-subunits (Navβ1, Navβ1B, Navβ2,
Navβ3 and Navβ4), in which α-subunits are necessary for
forming a functional ion-selective channel and β-subunits
affect ion channel gating and trafficking to regulate the
voltage-dependency and density of VGSC on the cell
membrane. It has been reported that mutation of Nav1.1,
a remarkable feature of Dravet syndrome, could induce
higher seizure activity and cognitive dysfunction [11].
Interestingly, Nav1.1 retained inside the cells while its
expression reduces markedly in BACE1-transgenic mice,
accompanied with disturbed Navβ2 [12]. And restoring
Nav1.1 level could reduce memory deficits in human
amyloid precursor protein (hAPP) transgenic mice [13].
Furthermore, elevated cell surface Nav1.2 expression con-
tributes to the epileptic behaviors in BACE1-null mice
[14]. These studies indicated that the abnormal Nav1.1/
Nav1.2 trafficking may be involved in dementia. Navβ2
plays a key role in the trafficking of α-subunits from
cytoplasm to cell membrane [15–17], and keeping the
steady-state stabilization of VGSC complexes at the
plasma membrane [18]. Interestingly, Navβ2 is also one
substrate for beta-secretase (BACE1) in BACE1-deficient
or over-expressing mice [19], and the increased Navβ2
cleavage contributes to aberrant neuronal activity and cog-
nitive deficits in amyloid precursor protein (APP) mice
[20]. However, the mechanism remains largely unclear.
Chronic brain hypoperfusion (CBH)-mediated chronic
cerebral ischemia and consequent cognitive impairment
[21, 22] is most likely to precede dementia [23, 24]. It has
been reported that CBH not only induces the accumula-
tion of beta-amyloid (Aβ) [21, 24] and cell death [25], but
also reduces dendritic arborizations as well as synaptic
contacts [26]. And acute cerebral ischemia by the
occlusion of right middle cerebral artery downregulates
the total Nav1.1 protein expression from 6 h to 2 days,
which was further increased from 3 to 7 days [27]. How-
ever, whether and how CBH influences the expression or
trafficking of Nav1.1/Nav1.2 has not been reported.
MicroRNAs are small non-coding RNA, which regu-
late protein synthesis. MicroRNA-9 (miR-9), enriched
in central nerve system (CNS) [28], contributes likely
to multi-pathological processes including the neuro-
genesis [29], proliferation [30], migration and differen-
tiation of neural progenitor cells [31], drug adaption
[32], adult brain plasticity [33], neural cell fate [34], the
migration and proliferation of glioma cells [35], axon
extension and branching [36], spinal motor neuron
development [37] under physiological status. Import-
antly, miR-9 expression has been downregulated in the
brain of patients with Huntington's disease [38] and up-
regulated in the patients with Alzheimer's disease [39],
suggesting that abnormal expression of miR-9 may be
involved at least partially in the processes of neurodegen-
erative diseases. Therefore, whether and how miR-9 par-
ticipates in the abnormal expression or trafficking of
Nav1.1/Nav1.2 induced by CBH is worth to be explored.
In this study, our data provide strong evidence that
miR-9 regulates Nav1.1/Nav1.2 trafficking by post-
transcriptional regulating SCN2B gene under CBH status.
Results
CBH-mediated Nav1.1/Nav1.2 trafficking defect in the
hippocampi and cortices
Previous studies have reported that Nav1.1/Nav1.2 traf-
ficking was changed after dementia [19, 20, 40]. Since the
functional protein of Nav1.1/Nav1.2 located in the mem-
brane, we first evaluated the surface expression of Nav1.1/
Nav1.2 and found that the surface expression of Nav1.1
and Nav1.2 was reduced both in the hippocampi and
cortices of 2VO rats (Fig. 1a, P < 0.01 vs sham). In order to
explore whether the decreased surface protein expression
of Nav1.1/Nav1.2 was due to the reduction of total
Nav1.1/Nav1.2 or the impairment of trafficking, the total
protein levels of Nav1.1/Nav1.2 were evaluated. The data
showed that the total protein levels of Nav1.1 and Nav1.2
were significantly increased in the hippocampi and corti-
ces of 2VO rats (Fig. 1b, P < 0.01 vs sham) rather than
reduced. These results suggested that the decreased
expression of Nav1.1/Nav1.2 on the cell membrane were
due presumably to the impaired trafficking of Nav1.1 and
Nav1.2 protein from cytoplasm to cell membrane in 2VO
rats rather than the changes of their total protein levels.
CBH-mediated Navβ2 downregulation in hippocampi
and cortices
Since Navβ2 is considered as an important regulator
for trafficking Nav1.1/Nav1.2 upon reports from others
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[16, 17] and our current observation (Fig. 2a), we then
investigate the expression of Navβ2 in either hippocam-
pus or cortex of 2VO rats. The protein expression of
Navβ2 was significantly decreased in both brain locations
compared with that in sham rats (Fig. 2b, P < 0.01). How-
ever, their mRNA expression of Navβ2 (SCN2B) was not
changed consistently with the protein expression of Navβ2
(Fig. 2c), suggesting that this may be ascribed to the post-
transcriptional regulation.
MiR-9-mediated post-transcriptional regulation of Navβ2
expression
MicroRNAs have long been known to control post-
transcriptional gene regulation and are essential for
neuronal function [41]. MiR-9 is enriched in CNS, and
increases in the brain of the patients with Alzheimer's
disease (AD) [39].To test potential involvement of miR-
9 in CBH-mediated 2VO rats, we also evaluated the ex-
pression of miR-9 in hippocampi and cortices of 2VO
rats. Surprisingly, the expression levels in both brain
regions were significantly increased compared with
those in sham control rats quantified using qRT-PCR
(Fig. 2d, P < 0.05).
Since the protein level of Navβ2 was reduced in both
hippocampi and cortices in 2VO rats, which is dis-
crepancy with the unchanged SCN2B expression, the
alternation of miR-9 is highly expected in this process.
By searching the database of microRNA targets (http://
www.targetscan.org/), we found that SCN2B has a
poorly conservative ‘seed’ sequence of miR-9 in its
3’UTR and the length of 3’UTR of SCB2B in rat was
very short based on the database of the University of
California Santa Cruz (UCSC) and the National Center
for Biotechnology Information (NCBI) Genome
Browsers. Since recent studies have reported that
microRNAs regulate protein expression by binding to
the coding regions of target protein [41–43], we then
searched RNA22/RNA hybrid (http://bibiserv.techfa-
k.uni-bielefeld.de/rnahybrid/) and found that the CDS
domain of SCN2B is likely to serve as potential targets for
miR-9. We next identified whether there are binding sites
for miR-9 on the CDS domain of SCN2B gene at the pos-
ition of 336–358 and 575–597 with highly conservative re-
gions (Fig. 3a). We subsequently screened the predicted
SCN2B binding sites using luciferase assays (see
Methods) and then selected constructs including pos-
ition 336–358 and position 575–597 of SCN2B CDS
domains that substantially suppressed luciferase ex-
pression in the presence of the matching microRNAs
(Fig. 3b). MiR-9 inhibited the SCN2B-CDS luciferase
activity compared with scrambled negative control
(Fig. 3b, P < 0.01), however, scrambled negative control
and inhibitor of miR-9 had no effect on luciferase activ-
ity compared with control group (Fig. 3b, P > 0.05), and
the difference of luciferase activity between inhibitor of
miR-9 and scramble negative inhibitor control was also
not detected (Fig. 3b, P > 0.05). For each of the two bind-
ing sites, we generated and tested several variants by intro-
ducing silent mutations designed to disrupt the putative
base pairings between the microRNAs and the corre-
sponding predicted targets. Silent mutations introduced
into the predicted targets at the position of 336–358 of
SCN2B CDS disrupted the ability of miR-9 to repress the
translation of the SCN2B-CDS (Fig. 3c, P < 0.01). How-
ever, simultaneous introduction of silent mutations at the
position of 575–597 of SCN2B CDS did not abolish the
Fig. 1 Nav1.1 and Nav1.2 trafficking were disturbed in hippocampi and cortices after chronic brain hypoperfusion (CBH). a, western-blot analysis
of the surface protein levels of Nav1.1 and Nav1.2 in sham and 2VO rats, upper: representative immunoblots of Nav1.1 and Nav1.2; lower: the
quantitative analysis data of the immunoblots. The optical density was evaluated for each band and values for 2VO rat tissue were normalized to
sham group after correction for protein loading with TfR,**P < 0.01 vs sham, mean ± s.e.m, n = 6. b, western-blot analysis of the total protein levels
of Nav1.1 and Nav1.2 in sham and 2VO rats, upper: representative immunoblots of Nav1.1, Nav1.2; lower: the quantitative analysis data of the
immunoblots. The optical density was evaluated for each band and values for 2VO rat tissue were normalized to sham group after correction for
protein loading with β-actin. **P < 0.01 vs sham, mean ± s.e.m, n = 6
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downregulation of SCN2B by miR-9 (Fig. 3c, P > 0.05). Si-
lent mutations introduced into both two predicted targets
at the positions of 336–358 and 575–597 of SCN2B CDS,
MutSCN2B-1 & 2 disrupted the ability of miR-9 to re-
press the translation of the SCN2B-CDS, strongly sug-
gesting that miR-9 uniquely targets at the position of
336–358, rather than 575–597, of SCN2B CDS.
To observe the influence of miR-9 on the protein
translation of SCN2B, we analyzed the protein levels of
Navβ2 in primary cultured neonatal rat neurons
(NRNs) co-transfected with miR-9 mimics. The suc-
cessful transfection of miR-9 was identified (Fig. 4a) by
qRT-PCR and Navβ2 protein levels were significantly
decreased in the presence of miR-9 (Fig. 4b). AMO-9
rescued the downregulation of Navβ2 elicited by over-
expression of miR-9 and scrambled negative control of
microRNA failed to affect the protein levels, suggesting
that miR-9 predominantly suppresses SCN2B transla-
tion (Fig. 4b,d). However, the mRNA level of Navβ2
was not changed in the presence of miR-9 (Fig. 4c),
which may ascribed to transcriptional regulation. To
verify the transcriptional mechanism of miR-9 on
Navβ2, the target protector technique was applied and
the results showed that the SCN2B target protector
Fig. 2 Navβ2 was decreased in hippocampi and cortices of rats after CBH. a, a model for Nav α-subunit trafficking after covalently binding to
Navβ2 subunit. b, western-blot analysis of Navβ2 in sham and 2VO rats, upper: representative immunoblots of Navβ2; lower: the quantitative
analysis data of the immunoblots. The optical density was evaluated for each band and values for 2VO rat tissue were normalized to sham group
after correction for protein loading with β-actin. **P < 0.01 vs sham, mean ± s.e.m, n = 6. c, The relative quantification of Navβ2 mRNA (SCN2B)
levels was detected by real-time PCR with normalized to β-actin, followed by further normalization to the values from sham brain tissues. P > 0.05
vs Sham, mean ± s.e.m, n = 3. d, miR-9 level detected by TaqMan real-time PCR in hippocampi and cortices from sham and 2VO rats after
normalization to U6 levels. *P < 0.05 vs sham, mean ± s.e.m, n = 3
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(oligodeoxynucleotides (ODNs)-miR) of miR-9 (the
position of 336–358 of SCN2B CDS) attenuated the
reduction in Navβ2 levels induced by miR-9 (Fig. 4e, P
< 0.01), implying that the SCN2B shows a great poten-
tial as the target for miR-9.
MiR-9-induced increase of total Nav1.1 /Nav1.2 protein in
vitro
To test the trafficking effect of miR-9 on Nav1.1/
Nav1.2, the protein expressions of Nav1.1 and Nav1.2
after pretreatment of NRNs with miR-9 were detected
by both Western blot and immunofluorescence tech-
niques. The results showed that miR-9 significantly
increased the expression of of Nav1.1 (Fig. 5a, P < 0.05)
and Nav1.2 (Fig. 5b, P < 0.05) total protein. And they
were prevented in the presence of AMO-9 (Fig. 5a,b).
The results were further observed by immunofluores-
cent analysis (Fig. 5c,d).
MiR-9-induced disturbances of Nav1.1/Nav1.2 trafficking
in vivo
To verify the functional role of miR-9 on Nav1.1/
Nav1.2 trafficking in vivo, miR-9 oligonucleotide car-
ried by lentivirus vector (lenti-pre-miR-9) was injected
directly into CA1 region of bilateral hippocampus of
each rat and significantly higher expression of miR-9 in
both hippocampi and cortices was observed at 8 weeks
after injection compared with the negative control
oligonucleotide (NC, Fig. 6a). Importantly, the expres-
sion of Navβ2 was also significantly decreased at mean-
time in lenti-pre-miR-9 group compared with control
group, which was reversed by lenti-pre-AMO-miR-9
(Fig. 6b, P < 0.01). The surface expressions of both
Nav1.1 and Nav1.2 proteins were markedly reduced in
both hippocampi and cortices of rats with lenti-pre-
miR-9 treatment, which was reversed by lenti-pre-
AMO-miR-9 (Fig. 6c-f, P < 0.05), even though the total
protein levels of Nav1.1 and Nav1.2 were increased in
Fig. 3 miR-9 regulates SCN2B evaluated by luciferase array. a, Complementarity between miR-9 seed-matched sequence and the region coding
for Navβ2 predicted by a computational and bioinformatics-based approach using RNA22/RNAhybrid. Two binding sites were found at the position of
336–358 of SCN2B CDS and the position of 575–597 of SCN2B CDS. The mutation made to genes are underlined. b, Luciferase reporter gene assay for
interactions between miR-9 and its binding sites in the CDS region of the Navβ2 mRNA in HEK293T cells. Cells were transfected with luciferase-target
motif chimeric vector alone, miR-9, AMO-9, or scramble negative control (NC) using lipofectamine 2000. **P < 0.01 vs NC, mean ± s.e.m. NC-inhibitors
means scramble negative inhibitor control, n = 3. c, Luciferase reporter gene assay for interactions between miR-9 and mutation of binding site in the
CDS region of SCN2B in HEK293T cells, **P < 0.01 vs NC, mean ± s.e.m, n = 3
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both hippocampi and cortices of rats with lenti-pre-
miR-9 treatment, which were reversed by lenti-pre-
AMO-miR-9 (Fig. 6c-f, P < 0.05). These data suggested
that miR-9 plays an important role in trafficking and
cellular distribution of Nav1.1/ Nav1.2.
Reversal effect of AMO-miR-9 on trafficking defects of
Nav1.1/Nav1.2 induced by 2VO
Our data displayed that 2VO results in miR-9 increase,
and over-expression of miR-9 then induces the
trafficking defects of Nav1.1/Nav1.2 in vitro. In order
to evaluate the protective effect of AMO-miR-9 on the
onset of the trafficking defects of Nav1.1/Nav1.2 in
2VO rats, lenti-pre-AMO-miR-9 was injected into the
hippocampus area. At 8 weeks after injection, miR-9
level was significantly decreased in both hippocampi
and cortices compared with 2VO rats (Fig. 7a).
To our interest, the decreased expression of Navβ2 was
also reversed by lenti-pre-AMO-miR-9 treatment in the
same brain regions (Fig. 7b, P < 0.01). And furthermore,
the surface protein expression of Nav1.1 was increased
and the total protein of Nav1.1 level was decreased by
lenti-pre-AMO-miR-9 compared with that in 2VO con-
trol rats (Fig. 7c,d, P < 0.05). Similarly, lenti-pre-AMO-
Fig. 4 MiR-9 downregulates the expression of Navβ2 proteins. a, Verification of uptake of miR-9 by NRNs after transfection, *P < 0.05 vs NC, #P <
0.05, mean ± s.e.m, n = 3 independent RNA samples for each group. b, Effects of miR-9 on protein levels of endogenous Navβ2 in primary cul-
tured neonatal rat neurons (NRNs), using western blot analysis. Cells were transfected with miR-9, AMO-9, miR-9 + AMO-9, or NC. mean ± s.e.m
from 3 batches of cells for each group. *P < 0.05, **P < 0.01 vs NC; ##P < 0.01 vs miR-9. c, Effects of miR-9 on SCN2B in primary cultured neonatal
rat neurons (NRNs) using qRT-PCR analysis. Cells were transfected with miR-9, AMO-9, miR-9 + AMO-9, or NC. mean ± s.e.m from 3 batches of cells for
each group. d, Representative confocal microscope images showing primary culture hippocampus neuron stained for Tubulin (green, upper), Navβ2
(red, middle). A merged image depicting double positivity (yellow) is shown on the bottom after transfection with miR-9 mimics or/and AMO-miR-9,
negative control, n= 3. e, Repression of Navβ2 by miR-9 using the miRNA-masking antisense oligodeoxynucleotides (ODNs) techniques in NRNs determined
by Western blot analysis, n = 3 batches of cells for each group, mean ± s.e.m, **P < 0.01 vs NC; ##P < 0.01 vs miR-9, ODN1 (oligodeoxynucleotides,
which masks the binding sites of miR-9, located in the position 336–358 of SCN2B CDS region); ODN-2 (oligodeoxynucleotides, which masks
the binding sites of miR-9, located in the position of 575–597 of SCN2B CDS region)
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miR-9 effectively improved the impaired trafficking of
Nav1.2 from cytoplasm to cell membrane under the
same experimental condition (Fig. 7e and f, P < 0.05).
Discussion
In this study, our observations have demonstrated, for
the first time that CBH induces the trafficking defects
of Nav1.1/Nav1.2 in hippocampi and cortices areas in
2VO rats, leading to the decrease in the expression of
Navβ2 protein. Further study has shown that the in-
creased miR-9 negatively regulated the expression of
Navβ2 protein by binding to the target in CDS region
of SCN2B gene. This observation provides a novel
mechanism to modify the reduction in Nav1.1/Nav1.2
membrane trafficking, and careful monitoring the
changes in miR-9 level and the expression for Nav1.1/
Nav1.2 and targeted gene are considerably necessary
during CBH.
Molecular identity and trafficking characters of
Nav1.1/Nav1.2 in rat brain after CBH
It has been known that Nav1.1, Nav1.2, and Nav1.6 are
abundant in the central nervous system, whereas
Nav1.3 is mostly present during embryonic stage [44].
Nav1.6 is concentrated in the axon initial segment
(AIS) nodes of Ranvier and in proximal dendrites in
many types of neurons [45]. Since cell surface levels of
Nav1.1 and Nav1.2 subunits dramatically decrease in
the brains of BACE1-trangenic mice although total
Nav1.1 and Nav1.2 levels are elevated [12, 14], and that
the axonal and surface levels of Nav1.2 are significantly
increased in hippocampal neurons from BACE1-null
mice [7]. In the present study, the expression of Nav1.1
Fig. 5 MiR-9 induced the increased of total Nav1.1 and Nav1.2 in primary cultured neonatal rat neurons (NRNs). a,b Effects of miR-9 on total protein
levels of endogenous Nav1.1 (a), Nav1.2 (b), in NRNs, using western blot analysis and . Cells were transfected with miR-9, AMO-9, miR-9 + AMO-9, or
NC. mean ± s.e.m from 3 batches of cells for each group. *P < 0.05 vs NC; #P < 0.05 vs miR-9. c-d,Representative confocal microscope images showing
primary culture hippocampus neuron stained for Tubulin (green, upper), Nav1.1 (C)/Nav1.2 (D) (red, middle). A merged image depicting double
positivity (yellow) is shown on the bottom after transfection with miR-9 mimics or/and AMO-miR-9, negative control
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and Nav1.2 of both surface and total protein were de-
tected in hippocampi and cortices of rat following CBH
and our data showed that CBH could induce trafficking
defects of Nav1.1/Nav1.2 with significant increase in
total protein levels of Nav1.1/Nav1.2 and the marked
decrease in surface protein levels of Nav1.1/Nav1.2.
The results are consistent with previous study per-
formed using BACE1-trangenic mice [12].
Previous studies have demonstrated that Navβ2 sub-
unit, an auxiliary subunit of Nav channel, participates in
channel trafficking, re-localization, and interaction of
both Nav1.1 [46, 47] and Nav1.2 [45]. Importantly, a
Fig. 6 MiR-9 produces the disturbance of trafficking, cellular distribution of Nav1.1 and Nav1.2 in rats. a, Detection of miR-9 in hippocampi and
cortices tissues after stereotaxic injection 8 weeks using qRT-PCR. Rats were transfected with lenti-pre- miR-9, lenti-pre-miR-9 + lenti-pre-AMO-miR-9,
or NC. Data was shown by mean ± s.e.m from 6 rats for each group. *P < 0.05 vs NC; #P < 0.05 vs lenti-pre- miR-9. b, Navβ2 protein expressions in
hippocampi and cortices tissues after treatment by lenti-pre-miR-9, lenti-pre-miR-9 + lenti-pre-AMO-miR-9, or NC for 8 weeks. c-f, Nav1.1 (C-D), Nav1.2
(E-F) total and surface protein expressions in hippocampi and cortices tissues after treatment by lenti-pre-miR-9, lenti-pre-miR-9 + lenti-pre-AMO-miR-9,
or NC for 8 weeks. *P < 0.05,**P < 0.01 vs NC; #P < 0.05, ##P < 0.01 vs lenti-pre- miR-9, mean ± s.e.m, n = 6
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recent study has also shown that the abnormal Navβ2
cleavage mediated by BACE1 affects Nav1.1 and Nav1.2
surface trafficking differentially [48]. Furthermore, in AD
status, the intracellular domain of Navβ2 functionally
regulates the α-subunit of VGSCs and the elevated
BACE1 activity leading to decrease in surface levels of
Nav1.1 in neuronal cells [49]. Interestingly, here we
found that CBH not only impaired Nav1.1/Nav1.2 traf-
ficking in rat hippocampi and cortices, but also down-
regulated the expression of Navβ2, suggesting Navβ2
may be more likely involved in the abnormal trafficking
of both Nav1.1 and Nav1.2 induced by CBH. Of noted,
previous studies have demonstrated that 2VO provokes
chronic brain hypoxia and triggers spatial memory
Fig. 7 AMO-miR-9 prevented the disturbed trafficking of Nav1.1/Nav1.2 induced by 2VO. a, Detection of miR-9 in hippocampi and cortices tissues
after stereotaxic injection 8 weeks using qRT-PCR. 2VO rats were transfected with lenti-pre-AMO-miR-9, or NC. Data was shown by mean ± s.e.m
from 6 rats for each group. *P < 0.05vs sham; #P < 0.05 vs 2VO. b, Navβ2 protein expressions in hippocampi and cortices tissues in 2VO rats with
or without lenti-pre-AMO-miR-9 treatment, or NC for 8 weeks. c-f, Nav1.1 (C-D), Nav1.2 (E-F) total and surface protein expressions in 2VO rats with
or without lenti-pre-AMO-miR-9 treatment, or NC for 8 weeks. *P < 0.05,**P < 0.01 vs sham; #P < 0.05, ##P < 0.01 vs 2VO, mean ± s.e.m, n = 6
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impairment in rats accompanied with elevation of APP
and BACE1 expression [24, 41]. Whether the impaired
trafficking of Nav1.1/ Nav1.2 in the present study is as-
sociated with CBH induced high level of APP and
BACE1 is unknown and need to be elucidated further.
Negative regulation of miR-9 on Navβ2 protein-mediated
trafficking disturbance of Nav1.1/Nav1.2 in vitro
As far as we know, microRNAs are newly discovered
and commonly considered as modulators of protein ex-
pression at post-transcriptional level, which are associ-
ated with the pathogenesis in multiple kinds of diseases
[50–53]. In the present study, our observations have
shown that the mRNA level for Navβ2 unaltered in hippo-
campi and cortices of 2VO rat but its targeted protein
expression significantly decreased (Fig. 2b), indicating that
the post-transcriptional regulation must be existed to
modify Navβ2 expression. It has been documented in the
literature that miR-9 is elevated in hippocampus [39] and
temporal lobe cortex [54] of AD patients, whereas, the op-
posite observation is also presented in AD patients [55]
from others,which was then demonstrated downregula-
tion of miR-9 due to overexpression of Aβ in hippocampal
cultures [56]. The discrepancies imply that the changes in
miR-9 in AD depend presumably upon the variants in-
ducers. In the present study, The major finding is that
miR-9 is significantly up-regulated under CBH conditions
in animal model (Fig. 2d).
Our study provides strong evidences that miR-9 in-
creases in both hippocampi and cortices, and inhibited
the expression of Navβ2, which in turn blocked the
trafficking of Nav1.1 and Nav1.2 from cytoplasm to
plasma membrane (Figs. 3, 4 and 5). However, why the
total Nav1.1/Nav1.2 protein levels increase in cultured
neuron following miR-9 treatment and how 2VO trig-
gers Nav1.1/Nav1.2 total protein up-regulation remain
unclear. The possible explanation may be due at least par-
tially to a unknown mechanism increasing protein synthe-
sis to compensate the trafficking defect-mediated the
decrease in surface expression of Nav1.1/Nav1.2. But the
detailed mechanism needs to be further studied.
In addition, our important finding here is that miR-9
regulates endogenous Navβ2 expression by targeting its
coding sequence (CDS) region rather than not 3’UTR of
SCN2B (Fig. 4). Additionally, another evidence collected
from the current inverstigation demonstrate that the
microRNA-mediated regulation is not limited to the
3’UTR, the functionality of target sites in the CDS also
confirmed by previous studies [57–59], such as miR-24
[58], miR-296, miR-470, miR-134 [60], miR-126 [43],
miR-181a [59], miR-148 [57] and miR-519 [61] that tar-
get sequences within the mRNA coding region have
been reported to repress the biosynthesis of the encoded
proteins in similar way. Our results provided another
evidence that, microRNA-mediated regulation is not
limited to target on the 3’UTR of genes, the functionality
of target sites is also located in the CDS domain.
Negative regulation of miR-9 on Navβ2 protein-mediated
trafficking defects of Nav1.1/Nav1.2 in vivo
More importantly, our in vivo study supports the data
collected from our in vitro observations that the upregu-
lation of miR-9 induced by both CBH and lenti-pre-
miR-9 could also disturb the trafficking of both Nav1.1/
Nav1.2 by downregulation of Navβ2 expression. On the
contrary, lenti-pre-AMO-miR-9 injection into hippo-
campus markedly prevents the abnormal trafficking of
both Nav1.1 and Nav1.2 following either CBH or lenti-
pre-miR-9 treated normal rats accompanied by increased
Navβ2 expression. These results combination with our
in vitro data suggested that the inhibition of miR-9 in
hippocampi and cortices in CBH model rats would be a
way to prevent sodium channel dysfunction after CBH.
An understanding of miR-9-Navβ2-Nav1.1/Nav1.2 traf-
ficking pathway could yield to the potential therapeutic
targets for the prevention of abnormal electrical activa-
tion induced by CBH.
Limitation and prospect
In the present study, though we have demonstrated the
regulation effect of miR-9 on the trafficking of Nav1.1/
Nav1.2 by inhibiting the expression of Navβ2 both in
vitro and in vivo, we did not provide evidence whether
these changes could induce abnormal sodium channel
currents and its dynamics characteristics in hippocampi
and cortices of 2VO rats. These need to be studied
further.
Conclusions
MiR-9 plays a key role in regulating the process of
Nav1.1/Nav1.2 trafficking via targeting on Navβ2 protein
in 2VO rats at post-transcriptional level, and inhibition
of miR-9 may be a potentially-valuable approach to pre-




Male Sprague–Dawley rats (weight 220–260 g, obtained
from the Animal Centre of the Second Affiliated Hospital
of Harbin Medical University, Harbin, Heilongjiang
Province, China) were housed at 23 ± 1 °C with 55 ± 5 %
of humidity and maintained on 12 h dark–light artificial
cycle (lights on at 07:00 A.M.) with food and water avail-
able ad libium. Rats used for operation of permanent,
bilateral common carotid artery occlusion (2VO) and
stereotaxic injection of the lentiviral vectors were anesthe-
tized with chloral hydrate (300 mg/kg, intraperitoneal)
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and maintained by administrating 0.5-1.0 % isoflurane.
The depth of anesthesia was monitored by detecting re-
flexes, heart rate and respiratory rate. Samples for qRT-
PCR, and Western blot assay were obtained from the
hippocampi and cortices of rats after anesthetized with
chloral hydrate (500 mg/kg, intraperitoneal) following by
confirmation of death by exsanguination. Tissues for pri-
mary neuron culturing were from neonatal SD rats after
administration of 20 % isoflurane and confirmation of death
by cervical dislocation. All animal procedures were ap-
proved by the Institutional Animal Care and Use Commit-
tee at Harbin Medical University (No.HMUIRB-2008-06)
and the Institute of Laboratory Animal Science of
China (A5655-01). All procedures were conformed to
the Directive 2010/63/EU of the European Parliament.
Permanent, bilateral common carotid artery occlusion
(2VO) in the rat
The method for preparation of 2VO rat was according to
the previous study [24, 62]. Briefly, after the rats were
anaesthetized, the bilateral common carotid arteries of
rats were exposed via a midline ventral incision, carefully
separated from the vagal nerves, and permanently ligated
with 5–0 silk suture. The wound was then closed and rats
were allowed recovering from anesthesia before being
returned to the animal facility.
Primary hippocampal and cortical neuron culture
The hippocampi and cortices regions were removed from
the postnatal day 0 (P0) rat pups. After tissues were dis-
sected and triturated, they were plated onto cell plates
precoated with 10 μg/mL poly-D-lysine (Sigma, St Louis,
MO, USA) and cultured in the culture media containing
neurobasal medium (Gibco, USA) with 2 % B27 supple-
ment (Invitrogen, USA) and 10 % fetal bovine serum (FBS,
HyClone, Logan, UT). After 3 days, the neurons were
treated with 5 μM cytosine arabinoside (Sigma, St Louis,
MO, USA) to inhibit astrocyte proliferation. For all experi-
ments, the neurons were used at 14 days after plating [24].
Synthesis of miR-9, AMO (anti-microRNA antisense
oligodeoxyribonucleotide)-miR-9 and other various
oligonucleotides
MiR-9 mimics (sense: 5’-UCUUUGGUUAUCUAGCUG
UAUGA-3’; antisense: 5’-AUACAGCUAGAUAACCAAA
GAUU-3’) and AMO-miR-9 (5’-UCAUACAGCUAGAUA
ACCAAAGA-3’) were synthesized by Shanghai Gene-
Pharma Co., Ltd (Shanghai, China). AMO-9 contains 2’-
O-methyl modifications at every base and a 3’ C3-con-
taining amino linker. Additionally, a scrambled RNA was
used as a negative control (sense: 5’-UUCUCCGAAC
GUGUCACGUAA-3, and antisense: 5’-ACGUGACACG
UUCGGAGAAUU-3’). The Navβ2-masking antisense oli-
godeoxynucleotides (ODNs) were synthesized by Shanghai
Sangon Biological Engineering Technology and Service
Co., Ltd. Navβ2 masking antisense-ODN-1 was 5’-AT
GCCTTCGTCTTCTAGCTGC-3’, which masks the bind-
ing sites of miR-9, located in the position 336–358 of
SCN2B CDS (coding sequence) region; Navβ2 masking
antisense-ODN-2 was 5’TCCTCTTCGGTCTTCAGGT
CA-3’, which masks the binding sites of miR-9, located in
the position of 575–597 of SCN2B CDS region. Five nucle-
otides or deoxynucleotides at both ends of the antisense
molecules were locked by a methylene bridge connecting
between the 2’-O- and the 4’-C atoms.
Transfection procedures
Thirty pmol/mL miR-9 and/or AMO-9, ODNs or NC
siRNAs were transfected into neonatal hippocampal and
cortical neurons with X-treme GENE siRNA transfection
reagent (Cat.#04476093001, Roche, USA) according to
the manufacturer’s instructions. Forty-eight hours after
transfection, cells were collected for total RNA isolation
or protein purification.
Construction of lentivirus vectors
Using the BLOCK-iT polII miR-RNAi expression vector
with the EmGFP kit from invitrogen, three single-
stranded DNA oligonucleotides were designed as follows:
(1) pre-miR-9 (“top strand” oligo: TGCTGTcTTTggTT
aTcTagcTgTaTgaGTTTTGGCCACTGACTGACTcaTa
cagagaTaaccaaaga) and its complementary chain (“bot-
tom strand” oligo: CCTGTcTTTggTTaTcTcTgTaTgaGT
CAGTCAGTGGCCAAAACTcaTacagcTagaTaaccaaagaC);
(2) pre-AMO-miR-9 (“top strand” oligo: TGCTGTcaTa-
cagcTagaTaaccaaagaGTTTTGGCCACTGACTGACTcTT
TggTTcTagcTgTaTga) and its complement (“bottom
strand” oligo: CCTGTcaTacagcTagaaccaaagaGTCAGTC
AGTGGCCAAAACTcTTTggTTaTcTagcTgTaTgaC); (3)
negative control (“top strand” oligo: tgctgAAATGTA
CTGCGCGTGGAGACGTTTTGGCCACTGACTGAC
GTCTCCACGCAGTACATTT) and its complement
(“bottom strand” oligo: cctgAAATGTACTGCGTGGA
GACGTCAGTCAGTGGCCAAAACGTCTCCACGCG
CAGTACATTTc). We then cloned the double-stranded
oligonucleotides (ds oligo) generated by annealling the
top and bottom strand oligos into the pcDNA™6.2-GW/
± EmGFP-miR vector and transformed the ligated mix-
ture into competent E. coli. After colony was purified
and identified as the correct expression clone, the pre-
microRNA expression cassette was transferred to other
Gateway® adapted destination vectors utilizing PolII
promoters and formed a new miRNA expression clone
containing attR substrates. The vector was identified
after analyzing the plasmid sequence (Invitrogen, USA).
The titers of the vectors used for experiments were
9.25 × 108 transducing U/ml. Virus suspensions were
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stored at −80 °C until use and were briefly centrifuged
and kept on ice immediately before injection.
Stereotaxic injection of the lentiviral vectors
After anaesthetized, rats were placed onto a stereotaxic
frame (RWB Life Science Co. Ltd, China) described as pre-
vious study [24]. Injection coordinates relative to the
bregma were as follows: AP (anteroposterior), −4.52 mm;
ML (mediolateral), ±3.2 mm; DV (dorsoventral), −3.16 mm
below the surface of dura using coordinates derived from
the atlas of Paxinos and Watson. Two microliters (10,000
Tu/μl) lenti-pre-miR-9 and/or Lenti-pre-AMO-miR-9 were
injected into CA1of the hippocampus using a 5 μl
Hamilton syringe with a 33-gauge tip needle (Hamilton,
Bonaduz, Switzerland). The needle was then maintained in
the place for another 2 min after injection and then with-
drawn very slowly to prevent the solution backflow.
Dual luciferase reporter assay
Before the luciferase activity assay, plasmid design and
construction was shown as in the below figure: a 707 bp
fragment from the coding region of SCN2B containing the
putative binding sequences for miR-9 (position 336–358
and position 575–597 of SCN2B CDS) was amplified by
PCR, cloned into the pSICHECK-2-control vector.
Mutagenesis nucleotides were carried out using direct
oligomer synthesis for the CDS region of Navβ2-binding
site 1 and Navβ2-binding site 2. Point mutations were
introduced into a possible miR-9 binding site located in
the coding region of SCN2B (position 336–358 and pos-
ition 575–597 of SCN2B CDS). MutSCN2B-1 represents
that “GACGAAGG” was mutated “ATCGATCG” in the
position 336–358 of SCN2B CDS, MutSCN2B-2 repre-
sents that “GACCGAAG” was mutated “ATCGATCG” in
the position 575–597 of SCN2B CDS. MutSCN2B-1&2
represents that both sites were mutated. All constructs
were sequence verified. Rat SCN2B CDS and mutSCN2B
CDS sequences were shown as following: SCN2B CDS
sequences (bold nucleotide showed the putative binding













































The sequence of miR-9 mimic is 5’-UCUUUGGUUAU
CUAGCUGUAUGA-3’ (synthesized based on the sequence
of rno miR-9 (miRBase Accession No. MIMAT0000781));
that of miR-NC is 5’-UUCUCCGAACGUGUCACGU
AA-3’; the sequence of the antisense 2’-O-methyl (2’-
O-Me) oligonucleotide for miR-9 is 5’-UCAUACAGC
UAGAUAACCAAAGA-3’, that of inhibitor-NC is
5’UUCUCCGAACGUGUCACGUTT-3’; HEK293T cells
(plated at 40 % ~ 50 % confluence) were transfected with
20 μmol/l miR-9, AMO-miR-9, or negative control siR-
NAs (NC) as well as 0.5 μg of psi-CHECKTM-2-target
DNA (firefly luciferase vector) and 1 μl blank plasmid
using lipofectamine 2000 (Invitrogen,USA) transfection
reagent according to the manufacturer’s instructions. After
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48 h of transfection, Firefly and renilla luciferase activities,
as indicated by relative luminescence units (RLU) were de-
termined using luciferase assay kits (Cat.#E1910, Promega,
USA) and luminometer (GloMaxTM 20/20, Promega,
USA) according to the manufacturer's instructions.
Quantitative real-time PCR- (qRT-PCR)
Total RNA was purified with the Trizol Reagent (Invi-
trogen, USA), according to the manufacturer’s instruc-
tions as described previously [24]. MiR-9 level was
quantified by the TaqMan® MicroRNA Reverse Tran-
scription Kit (Cat.# 000583, ABI, Roche, Branchburg, NJ)
and the TaqMan® Gene Expression Master Mix (Cat.#
1108123, Applied Biosystems). The TaqMan qRT–PCR
probes and primers for miR-9, were designed by Applied
Biosystems [63]. U6 was used as an internal control. The
SYBR Green PCR Master Mix Kit (Applied Biosystems,
Cat#4309155) was used for real-time PCR to quantify the
SCN2B mRNA in our study. β-actin was used as an
internal control. Primers are as following: SCN2B
forward: CTCTCTGAACTGGACTTACC and SCN2B
reverse: GGTTGGTGATGTAGCAGTTG; β-actin for-
ward: GGAAATCGTGCGTGACATTA and β-actin re-
verse: AGGAAGGAAGGCTGGAAGAG. All reactions
were performed in triplicate, and the expressions of
microRNAs data were shown as Delta-Delta Ct method.
Western blot
Both the total protein and surface protein samples were
extracted from hippocampi and cortices of rats or pri-
mary cultured neurons for immunoblotting analysis. For
the total protein analysis, frozen tissue was homogenized
with 1000 μl solution contained 40 % SDS, 60 % RIPA
and 1 % protease inhibitor in each 200 mg brain tissue.
The homogenate was then centrifuged at 13,500 rpm for
30 min and the supernatants (containing cytosolic and
membrane fractions) were collected. The method of sur-
face protein extraction was using Mem-PER Eukaryotic
Membrane Protein Extraction Reagent Kit (Cat# 89826,
Pierce Biotechnology, USA) according to the manufac-
turer's instructions. Protein concentrations were mea-
sured spectrophotometrically using a BCA kit (Universal
Microplate Spectrophotometer; Bio-Tek Instruments,
Winooski, VT, USA). Protein samples were fractionated
by SDS-PAGE (10 % polyacrylamide gels for sodium
channels) then transferred to PVDF membrane. The
primary anti-Nav1.1, Nav1.2, Navβ2 antibodies (Cat#
ASC-001,1:200, RRID:AB_2040003; Cat# ASC-002,1:200,
RRID:AB_2040005; Cat# ASC-007, 1:200, RRID:AB_204
0011, Alomone Labs, Jerusalem, Israel) were used and β-
actin (Kangcheng, Shanghai, China) β-actin (Kangcheng,
Shanghai, China) was selected as an internal control of
total proteins, mouse anti-human transferrin receptor
(TfR) (Cat# 13–6800, RRID:AB_2040011, Invitrogen,
USA) was selected as an internal control of surface pro-
teins. Western blot bands were captured on the Odyssey
Infrared Imaging System (LI-COR Biosciences, Lincoln,
NE, USA) and quantified with Odyssey v1.2 software by
measuring the band intensity (area × OD) in each group
and normalizing to the internal control.
Immunocytochemistry staining
The cultured neonatal rat neurons were transcardially
perfused by 4 % buffered paraformaldehyde, pH7.4. After
blocking, cultured neonatal rat neurons were incubated
with the anti-β-Tubulin III (neuronal) antibody (Cat no.
T8578; 1:5000; Sigma, Saint Louis, USA) or anti- Nav1.1,
Nav1.2, Navβ2 antibodies (Alomone Labs, Jerusalem,
Israel) overnight at 4 °C, and then the cultured neonatal
rat neurons were washed and incubated with the sec-
ondary antibodies conjugated to Alexa Fluor 488 and
Alexa Fluor 594 (Molecular Probes, Eugene, OR, USA)
for 1 h at room temperature.
Statistical analysis
Data were described as mean ± s.e.m for experimental
data. The two-tailed Student’s t-test was applied for
comparisons between the two groups. Multi-group’s
comparisions were performed by One-way ANOVA.
SPSS19.0 software was used for all statistical analyses.
P < 0.05 was considered significant.
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